This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange closed up 5.95 points to 715.36 Friday, but it ended the week down 0.23 point. Darren Stark's halted capital pool shell, Anchor Capital Corp. (ANC), plans to acquire Intraline Medical Aesthetics Pty. Ltd. for its qualifying transaction. The shell will roll back 1 for 2.5, leaving it with 2,205,600 postconsolidated shares issued, then issue 14,258,714 postconsolidated shares to Intraline's shareholders. Anchor Capital will also issue another 1,287,714 postconsolidated shares in total to Intraline's president, Terry Fraser, and its chief executive officer, Reece Tomlinson, as settlement for salaries owed to them.

Intraline is a Kelowna-based manufacturer of cosmetic products. In October, 2015, it launched its line of dermal fillers. These are injectable liquids or gels that fill the spaces below wrinkles and hollow cheeks. The company explains that its dermal fillers are not like Botox (botulinum toxin), for three reasons. First, the fillers are injected into skin, not muscle. Second, the fillers contain no neurotoxins. Third, if a customer is unhappy with her dermal filler treatment, then she can have it reversed. This is not possible for a Botox treatment; one would need to wait two to six months for the Botox effect to wear off. Intraline Medical also has a moisturizer and a face mask, and it has more products in development.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS